ARCHIVES

DCT Board Okays Contract Recompetitions, But Litton Bionetics May Be Barred From Two Supporting Gall’s Lab, Plus FCRF Program

This article is from The Cancer Letter archive.

Vol. 11 No. 41 | October 25, 1985

Download PDF Visit The Full Archive

Related Articles

UHC Expands Risk Models To Include 25 Cancer Variables

February 24, 2012

MSKCC oncologist settles insider trading case with SEC.

November 11, 2005

Bezwoda’s ’95 Phase II Study Entirely A Sham, Audit Finds.

April 27, 2001

Home-Based Program Helps Older Cancer Survivors

May 29, 2009

Possible Breach of Patient Confidentially By Calif. Physician; NCI

May 6, 1994

Public Forum On NRSA Tuition Policies

April 14, 1995